Ambusol's mission is to transform the treatment landscape for glioblastoma multiforme (GBM) by introducing a groundbreaking therapy that targets cancer cells with precision, aiming to improve patient outcomes and quality of life. With a focus on innovation and minimizing side effects, Ambusol AB is dedicated to providing new hope for patients facing this aggressive form of brain cancer. Headquartered in Sweden, the company is poised to expand its impact globally, with plans to extend its pioneering approach to other challenging cancers in the future.
